CORESTEMCHEMON Inc.

A166480

KR7166480004

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
11,530 ^KRW	-1.37%		-2.45%	+70.31%

Mar. 26	CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI
Mar. 22	CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	CI

CORESTEMCHEMON Inc. announced that it has received KRW 32.31145 billion in funding from a group of investors

January 25, 2023

On January 26, 2023, CORESTEMCHEMON Inc. closed the transaction.

Latest news about CORESTEMCHEMON Inc.

CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	Mar. 25	CI
CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	Mar. 21	CI
CORESTEMCHEMON Inc.(KOSDAQ:A166480) dropped from S&P Global BMI Index	23-08-24	CI
CORESTEMCHEMON Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-14	CI
CORESTEMCHEMON Inc. announced that it has received KRW 32.31145 billion in funding from a group of investors	23-01-25	CI
CORESTEMCHEMON Inc. announced that it expects to receive KRW 32.31145 billion in funding from a group of investors	23-01-16	CI
CORESTEMCHEMON Inc. announced that it has received KRW 10.81145 billion in funding	22-12-31	CI
CORESTEM Inc. completed the acquisition of the remaining 47% stake in ChemOn Inc..	22-11-30	CI
CORESTEM Inc. agree to acquire remaining 47% stake in ChemOn Inc. for KRW 90 billion	22-08-15	CI
CORESTEM Inc. announced that it has received KRW 41 billion in funding from a group of investors	20-06-25	CI
Corestem, Inc. announced that it expects to receive KRW 41 billion in funding from a group of investors	20-06-24	CI
Kadimastem Ltd. announced that it expects to receive $7 million in funding from Corestem, Inc.	16-12-06	CI
Corestem, Inc.(KOSDAQ:A166480) added to Russell Global Index	15-10-01	CI
Corestem, Inc.(KOSDAQ:A166480) added to S&P Global BMI Index	15-09-21	CI
Corestem, Inc. has completed an IPO in the amount of KRW 40.00 billion.	15-06-23	CI
Corestem Co., Ltd. has filed an IPO.	15-03-23	CI

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CORESTEMCHEMON INC.	+70.31%	178M
IQVIA HOLDINGS INC.	+0.17%	42.19B
MODERNA, INC.	+10.92%	42.24B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+5.23%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.2B
MEDPACE HOLDINGS, INC.	+26.69%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.57%	10.4B